Qué está moviendo el mercado.

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Stock chart with numbers going down ©Shutterstock Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.05% in pre-market trading on Monday after the company reported fiscal third-quarter results that fell well short of analyst expectations, d…

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of…

Citius raises $36.5m for Lymphir commercialisation

Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy. The therapy is approved by the U…

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following the December 2025 commercial launch of…

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institu…

Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cel…

Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment

[Cancer cell view] * Citius Oncology (CTOR [https://seekingalpha.com/symbol/CTOR]) shares jumped after the commercial launch of its immunotherapy Lymphir, a late-line option for cutaneous T-cell lymphoma, in the U.S. * The drug was approve…

How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch

In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for certain cutaneous T-cell lymphoma patients,…

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citi…

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J., Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius O…

Citius Oncology Raises $9 Mln Through Direct Offering And Private Placement

(RTTNews) - Citius Oncology, Inc. (CTOR), a subsidiary of Citius Pharmaceuticals, Inc., has entered into a securities purchase agreement with an institutional investor for a registered direct offering of 5,142,858 shares of common stock. I…

Citius Oncology deploys AI platform to support LYMPHIR launch

NEW JERSEY - Citius Oncology, Inc. (NASDAQ:CTOR) has implemented an artificial intelligence platform to enhance its commercial operations ahead of the anticipated launch of LYMPHIR, a treatment for cutaneous T-cell lymphoma (CTCL), the com…

Citius Oncology Beats Fiscal Q3 EPS

Key Points GAAP loss per share of ($0.08) for Q3 FY2025 beat analyst expectations by $0.07 No revenue was reported for Q3 FY2025, as LYMPHIR has not yet launched commercially.These 10 stocks could mint the next wave of millionaires › Citiu…

Form 8K Citius Oncology Inc For: 12 August

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /CNW/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasi…

Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion

Cencora recently executed a distribution services agreement with Citius Oncology, signaling an expansion in its pharmaceutical distribution capabilities. Over the past quarter, Cencora’s share price rose by 4.4%, aligning with the market t…

Cencora distribution deal boosts Citius shares

[Gratitude Concept With Heart Symbol] Eoneren * Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius On…

Citius Oncology launches $15M equity and warrant offering; shares down

* Citius Oncology (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]) is offering up to $15M in common stock and accompanying warrants. * The offering includes up to $15M in pre-funded warrants and up to $15M in regular warrants, each con…

Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Citius Pharmaceuticals, announced that it…

Catalyst Watch: Amazon Prime Day, Delta earnings and stock-by-stock trade deal implications

[Business and stock exchange data on the screen.] Torsten Asmus Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next w…

US High Growth Tech Stocks with Promising Potential

The United States market has shown robust performance recently, climbing 3.4% in the last 7 days and rising 14% over the past year, with earnings forecast to grow by 15% annually. In this thriving environment, identifying high growth tech…

Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings

[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MOND…

VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%

(RTTNews) - What's driving the momentum in the following stocks? Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual-target fusion protein approved in China…

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.08%

Investing.com – U.S. stocks were mixed after the close on Friday, as gains in the Oil & Gas, Consumer Goods and Telecoms sectors led shares higher while losses in the Basic Materials, Technology and Healthcare sectors led shares lower. At…

Citius Oncology enters distribution services agreement with Cardinal Health

Citius Oncology (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]), has entered into a distribution services agreement with C…

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citi…